JENKEM(SH:688356)2021-04-29 16:00Financial Performance - Operating revenue surged by 158.77% to CNY 69,918,824.65 year-on-year[12] - Net profit attributable to shareholders rose by 229.52% to CNY 35,993,273.76 compared to the same period last year[12] - Basic earnings per share increased by 150.00% to CNY 0.60 compared to the same period last year[15] - Total revenue for Q1 2021 reached ¥69,918,824.65, a significant increase from ¥27,019,555.82 in Q1 2020, representing a growth of approximately 159.5%[46] - Net profit for Q1 2021 was ¥35,993,273.76, compared to ¥10,922,899.96 in Q1 2020, marking an increase of about 229.5%[46] - Operating profit for Q1 2021 was ¥41,925,586.26, compared to ¥12,650,445.57 in Q1 2020, indicating an increase of approximately 230.5%[46] - Total comprehensive income for Q1 2021 was ¥35,552,598.07, compared to ¥11,180,337.22 in Q1 2020, reflecting an increase of approximately 218.5%[48] Cash Flow - Net cash flow from operating activities reached CNY 6,243,487.18, a significant recovery from a negative cash flow of CNY -2,082,630.90 in the previous year[12] - Cash flow from operating activities totaled 5,409,702.26 RMB, significantly higher than 1,949,731.18 RMB in the previous year, marking an increase of 177%[51] - Cash inflow from operating activities totaled ¥150,705,302.53 in Q1 2021, compared to ¥30,078,702.51 in Q1 2020[49] - The net cash flow from investing activities was -329,617,861.24 RMB, worsening from -111,943.01 RMB year-over-year[51] Assets and Liabilities - Total assets increased by 6.59% to CNY 959,920,354.30 compared to the end of the previous year[12] - Current assets totaled ¥827,235,566.31, up from ¥785,063,564.10, indicating an increase of about 5.7% year-over-year[36] - Total liabilities amounted to ¥63,475,457.92, up from ¥44,368,069.83, reflecting an increase of about 43%[39] - Shareholders' equity reached ¥896,444,896.38, compared to ¥856,243,364.98, indicating a growth of approximately 4.7%[39] - The company reported a significant increase in contract liabilities, which rose to ¥13,347,437.09 from ¥4,855,882.81, representing an increase of about 175%[39] Shareholder Information - The total number of shareholders at the end of the reporting period was 3,788[16] - The largest shareholder, Xuan Zhao, holds 24.78% of the shares, totaling 14,866,610 shares[16] Research and Development - R&D expenditure as a percentage of operating revenue decreased by 7.76 percentage points to 8.73%[15] - Research and development expenses increased by 37.02% to ¥6,103,116.00, driven by higher labor and outsourcing costs[28] - Research and development expenses in Q1 2021 totaled ¥6,103,116.00, up from ¥4,454,023.05 in Q1 2020, representing a rise of about 37%[46] Government Subsidies - The company reported a government subsidy of CNY 26,147.58 related to its normal business operations[15] Inventory and Receivables - Accounts receivable increased by 84.21% to ¥84,938,751.66, reflecting a rise in operating income[22] - Prepayments surged by 741.57% to ¥21,423,173.15, primarily due to the investment project in medical polyethylene glycol[22] - Inventory increased to ¥26,557,562.66 from ¥23,436,550.08, showing a growth of approximately 9%[36] Capital Structure - The company maintained a stable capital reserve of ¥611,039,649.20, slightly increasing from ¥606,390,715.87[39] - The company has a total of $606.39 million in capital reserves, showcasing robust financial health[61] - Shareholders' equity stood at approximately $721.26 million, reflecting a stable capital structure[61] Other Financial Metrics - The weighted average return on net assets decreased by 0.71 percentage points to 4.12%[12] - The company reported a 243.40% increase in income tax expenses to ¥5,932,312.50, attributed to higher sales revenue and total profit[30] - The company experienced a credit impairment loss of ¥1,750,060.07 in Q1 2021, compared to a loss of ¥364,519.88 in Q1 2020, reflecting a deterioration in credit quality[46]